Canadian Cardiovascular Society (CCS) MYocarditis and/or pericarditis following mRNA COVID-19 VACCination (MYCOVACC) national surveillance study
The MYCOVACC study is a multi-centre, pan-Canadian study funded by the Public Health Agency of Canada. The CCS is collaborating with researchers, research networks, patients, and public health authorities from across the country to conduct the study. The Canadian Congenital and Pediatric Cardiology Research Network is a key partner in this initiative.
Most cases of myocarditis and pericarditis after mRNA COVID-19 vaccination are mild and resolve themselves, but the longer-term effects are currently unknown. This study will help determine if people who experience these rare heart conditions after receiving an mRNA COVID-19 vaccine are at risk of future health problems.
The study will:
1. Describe health and functional outcomes in adults and children who experience myocarditis and/or pericarditis after mRNA COVID-19 vaccination.
2. Assess recovery of the heart in adults and children who experience myocarditis and/or pericarditis after mRNA COVID-19 vaccination.
Study participants are assessed by a participating specialist using a clinical protocol at 3 months and 12 months after diagnosis and then annually for up to 3 years. They are also asked to complete quality of life, mental health, physical activity, and health outcome questionnaires.
The study will inform clinical guidance for COVID-19 vaccination. It will provide important information to help Canadian public health agencies and government decision-makers develop vaccine programs for boosters and new variants.
The project will also support public trust in vaccine safety and increase confidence in COVID-19 vaccines, especially among young people and their parents. A good understanding of what happens to those who experience myocarditis and/or pericarditis after an mRNA COVID-19 vaccine will inform discussions with Canadians of all ages about vaccination.
To learn more about MYCOVACC: https://ccs.ca/mycovacc/
Production of this document has been made possible through a financial contribution from the Public Health Agency of Canada. The views expressed herein do not necessarily represent the views of the Public Health Agency of Canada.